Hatch-Waxman Reforms Would Have Generics Pick A Lane

Drug Industry Daily
A A
Challengers of brand name drug patents would have to choose between litigating under Hatch-Waxman or through inter partes review under legislation introduced in both the Senate and House on Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily